The Expression of Th17-Associated Cytokines in Human Acute Graft-versus-Host Disease  by Liu, Yuejun et al.
Biol Blood Marrow Transplant 19 (2013) 1421e1429American Society for Blood
ASBMT
and Marrow TransplantationBiology
The Expression of Th17-Associated Cytokines in Human
Acute Graft-versus-Host Disease
Yuejun Liu 1, Yifeng Cai 1,y, Lan Dai 1, Guanghua Chen 1, Xiao Ma 1,
Ying Wang 1, Ting Xu 1, Song Jin 1, Xiaojin Wu1, Huiying Qiu 1, Xiaowen Tang 1,
Caixia Li 1, Aining Sun 1, Depei Wu 1,*, Haiyan Liu 1,2
1 Laboratory of Cellular and Molecular Tumor Immunology, Cyrus Tang Hematology Center, Department of Hematology, The First
Afﬁliated Hospital of Soochow University, Jiangsu Institute of Hematology and Key Laboratory of Thrombosis and Hemostasis
Ministry of Health, Suzhou, China
2 Jiangsu Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou, ChinaArticle history:
Received 11 December 2012
Accepted 13 June 2013
Key Words:
Acute graft-versus-host disease
Allogeneic hematopoietic cell
transplantation
Regulatory T cells
Th17 cellsFinancial disclosure: See Acknowle
* Correspondence and reprint r
Hematology, Jiangsu Institute of He
Soochow University, Suzhou, Jiang
E-mail address: wudepei@med
y Current address: Yifeng Cai, De
Hospital of Nantong University, Na
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
The role of Th17 cells and Th17-associated cytokines in the development of acute graft-versus-host disease
(aGVHD) in clinical allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients is not well
established. In the current study, a cohort of 69 allo-HSCT patients was examined for the percentages of Th17
and FoxP3þ Treg cells and the expressions of RORgt and FoxP3 in peripheral blood mononuclear cells
(PBMCs). The Th17 percentage and RORgt expression were signiﬁcantly higher, whereas Treg percentage and
FoxP3 expression were signiﬁcantly lower in severe aGVHD (grade 3 to 4) and mild aGVHD (grade 1 to 2)
patients than in patients without aGVHD (grade 0) and healthy donors. We then investigated the expressions
of Th17-associated cytokines, including TGF-b, IL-6, IL-1b, IL-17, IL-21, IL-22, IL-23, as well as IL-23R in the
PBMCs of patients after allo-HSCT. The expressions of IL-17 and IL-22 in CD4þ T cells were also examined. The
results showed that the expressions of IL-6, IL-1b, IL-17, IL-21, IL-23, and IL-23R were all increased, whereas
IL-22 expression was decreased in aGVHD patients. The changes were also correlated with the severity of
aGVHD. We also investigated the dynamic changes of Th17/Treg cells and Th17-associated cytokines in
patients during the onset and resolution of aGVHD. The results demonstrated a reciprocal relationship
between Treg and Th17 cells. Th17-associated cytokine expressions, namely IL-17 and IL-23, were closely
related to the occurrence and resolution of aGVHD. We conclude that the dynamic balance between the Th17
and FoxP3þ Treg cells and the changes of Th17-associated cytokines could be the indicators of the disease
progression and promising candidates of prognostic biomarkers of aGVHD.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION that circulating and/or tissue localized Th17 cells can be
Acute graft-versus-host disease (aGVHD) is a leading
cause of nonrelapse mortality following allogeneic hemato-
poietic stem cell transplantation (allo-HSCT) [1]. aGVHD is
a systemic disease mainly targeting the skin, liver, and
gastrointestinal tract [2,3]. It is characterized by exaggerated
inﬂammatory responses, during which the production of
proinﬂammatory cytokines enhances the ability of donor T
lymphocytes to attack the host tissues and to produce more
proinﬂammatory cytokines, perpetuating the disease process
by contributing to the cytokine storm that initiates aGVHD.
Th17 cells were characterized by production of
interleukin-17 (IL-17) A, IL-17F, IL-21, and IL-22 [4-7]. Th17
differentiation requires TGF-b and IL-6 [8]. Stabilization of
Th17 phenotype requires IL-23, together with TNF and IL-1b,
whereas their expansion is mainly dependent on IL-21 [9,10].
Studies with murine models showed conﬂicting results, with
some data suggesting that Th17 is protective [11] and others
indicating a pathogenic role in aGVHD [12,13]. In humans,
there are also divergent results with retrospective reportsdgments on page 1429.
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13.06.013increased [14,15] or decreased [16] in aGVHD. Although the
role of Th17 in aGVHD needs to be further determined, some
Th17-related cytokines, particularly IL-6 and IL-23, have been
shown to play critical roles in aGVHD [17-21]. Furthermore,
both IL-21 blockade and abrogation of donor T cell IL-21
signaling reduced GVHD mortality [22,23]. On the other
hand, a recent study showed that IL-22 regulated tissue
sensitivity to aGVHD and protected mice from aGVHD tissue
damage and mortality [24]. Despite the extensive studies in
the murine models, the expression of Th17-related cytokines
in aGVHD patients is not well studied.
CD4þCD25þFoxP3þ regulatory T cells (Tregs) play
a pivotal role in regulation and maintenance of immune
tolerance to self-antigens. Many studies have shown that the
increasing frequencies of Tregs are associated with a lower
incidence of aGVHD in patients who have undergone allo-
HSCT [25-29]. It has been suggested that the Th17/Treg
ratio could be a sensitive and speciﬁc biomarker of aGVHD.
Therefore, the balance between Treg and Th17 may be
essential for maintaining immune homeostasis in aGVHD
patients. However, the decrease of Tregs was correlated with
increases in the frequency of Th17 cells only in a very small
subset of patients in 1 study [14].
The aim of this study was to determine the percentages of
peripheral Treg and Th17 cells and the expression of their
related cytokines in aGVHD patients. We also monitored the
dynamic changes of Treg and Th17 cells, as well as IL-17,Transplantation.
Table 1
Clinical Characteristics of Patients (n ¼ 69)
Characteristics n (%)
No. of patients 69
Age, yr, median (range) 34 (11 to 57)
Sex (female/male) 28/41
Diagnosis
Acute lymphoblastic leukemia 20 (29.0)
Acute myeloid leukemia 29 (42.1)
Chronic myeloid leukemia 7 (10.1)
Lymphoma 2 (2.9)
Myelodysplastic syndrome 6 (8.7)
Severe aplastic anemia 4 (5.8)
Paroxysmal nocturnal hemoglobinuria 1 (1.4)
Conditioning regimen
Bu-based 52 (75.4)
TBI-based 14 (20.3)
FluþCTXþATG 3 (4.3)
Acute GVHD grade
1 12 (17.4)
2 16 (23.2)
3 5 (7.2)
4 12 (17.4)
Site of aGVHD
Skin 14 (20.3)
Liver 2 (2.9)
Gut 20 (29.0)
Multiorgans 9 (13.0)
Donor type
Sibling 39 (56.5)
MUD 20 (29.0)
Haplo-HSCT 7 (10.2)
UCBT 3 (4.3)
Days to aGVHD onset, median (range) 32 (15 to 94)
Bu indicates busulfan; TBI, total body irradiation; GVHD, graft-versus-host
disease; MUD, matched unrelated donor; Haplo-HSCT, haploidentical
hematopoietic stem cell transplantation; UCBT, umbilical cord blood
transplantation; Flu, ﬂudarabine; ATG, antithymocyte globulin; CTX,
cyclophosphamide.
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These studies provided important evidence in human aGVHD
that Treg and Th17 cells played important roles during
aGVHD, and some of their related cytokines could be tar-
geted for therapeutic purposes.
PATIENTS, MATERIALS, AND METHODS
Patients and Data
Sixty-nine patients who underwent allo-HSCT between August 2010
and September 2011 at the Center for Hematopoietic Stem Cell Trans-
plantation at the First Afﬁliated Hospital of Soochow University were
included in this study. The characteristics of these patients are shown in
Table 1. Informed consent was obtained from all patients, with approval of
the institutional review board. The conditioning regimen consisted of either
busulfan (.8 mg/kg intravenously [i.v.] every 6 hours for 12 doses) followed
by cyclophosphamide (CTX) (1.8 g/m2/day for 2 days) or total body irradi-
ation (TBI) (850 cGy daily for 1 day) followed by Cy. All patients with
matched unrelated donor transplantations and haplo-identical related
donor transplantations were given ATG (Thymoglobulin; Sangstat, Fremont,
CA) 4 mg/kg/day to 8 mg/kg/day for 3 to 5 days, given from day -5 or day -3
until day -1. Twenty-three patients were given peripheral blood stem cells
(PBSCs) from donors treatedwith granulocyte colony-stimulating factor. The
other 46 patients received mobilized bone marrow (BM) cells plus PBSCs.
GVHD prophylaxis consisted of a combination of either cyclosporine A (CsA)
and short-term methotrexate (MTX) or CsA, short-term MTX, and myco-
phenolate mofetil. The dosage of CsA was 2.5 mg/kg/day, i.v. from day -9.
MMF was administered orally, .5 g every 12 hours from day -9 to engraft-
ment. The dosage of MTX was 15 mg/m2 administered i.v. on day þ1 and
10 mg/m2 on days þ3, þ6, and þ11.
Before initiation of the treatment, patients underwent a thorough
evaluation to ascertain the severity and extent of their aGVHD, including
a physical examination, laboratory evaluations, and a consultation without
the tissue biopsy results. Each organ (skin, liver, and gut) was staged 1
through 4 for aGVHD according to modiﬁed criteria based on the schema of
Glucksberg et al. [30]. Patients were also assigned a grade of aGVHD (1
through 4) based on overall severity [31]. aGVHDgrade 2 was treated withhigh-dose methylprednisolone starting at 2 mg/kg/day, MTX, and a CD25
monoclonal antibody (Novartis, Basel, Switzerland) was given to subjects
intolerant of or unresponsive to methylprednisolone. Acute GVHD <grade 2
was treated by increasing the dose of post-transplantation immune
suppressive drugs and/or substituting FK506 for CSA.
We analyzed samples from patients at onset of aGVHD (grade 1 to 4)
(n¼ 45) and time-matched samples from patients without aGVHD (grade 0)
(n ¼ 24). Peripheral blood samples were collected as soon as aGVHD was
diagnosed and before therapy was begun. We also collected blood samples
from 18 age-matched healthy donors as controls.
Flow Cytometry and Intracellular Cytokine Staining
PBMCs were separated by density gradient centrifugation with
lymphocyte separationmedium (Invitrogen Life Technologies, Carlsbad, CA).
FoxP3 was detected using a human regulatory T cell whole blood staining kit
(eBioscience, San Diego, CA) according to the manufacturer’s instructions.
Brieﬂy, the human blood cells were ﬁrst surface-stained with anti-CD4mAb.
After ﬁxation and permeabilization, cells were stained with anti-
Foxp3 PE and analyzed on a BD FACScan (Becton Dickinson [BD], San Jose,
CA). For IL-17 and IFN-g staining, PBMCs were incubated for 4 hours with
50 ng/mL phorbol myristate acetate and 750 ng/mL ionomycin (both from
Beyotime Biotechnology, Haimen, China) in the presence of 5 g/mL brefeldin
A (eBioscience, San Diego, CA) in a tissue culture incubator at 37C and 5%
CO2. The cells were labeled with anti-CD4 mAbs. Afterward, cells were ﬁxed
and permeabilized with FACS Permeabilizing Solution (Becton Dickinson)
and stained with anti-IFN-g-APC (eBioscience, San Diego, CA) and anti-IL-
17-PE mAbs (BD Pharmingen, SanDiego, CA). As a control, cells were also
stained with isotypemAbs. Cells were washed in ice-cold PBS that contained
BSA (.1%) and azide (.01%) and analyzed on a BD FACScan using Cell Quest
software (BD Biosciences, San Jose, CA).
Isolation of Human CD4þ T Cells
CD4þ T cells were puriﬁed from patients’ peripheral blood using Human
CD4þ T cell Enrichment Cocktail (Stemcell, Vancouver, BC). Brieﬂy, Human
CD4þ T Cell Enrichment Cocktail was added at 50 ml/mL of whole blood and
incubated for 20 minutes at room temperature. Samples were diluted with
an equal volume of PBS þ 2% fetal bovine serum (FBS) (Gibco, Grand Island,
NY) and mixed gently. Diluted samples were then layered on top of the
density medium (Pharmacia, Piscataway, NJ) and centrifuged for 20 minute
at 1200 g at room temperature. The enriched cells were collected from the
density medium for RNA extraction.
RNA Extraction and Real-Time Quantitative Reverse Transcription
Polymerase Chain Reaction (PCR)
Total RNAwas isolated from PBMCs or CD4þ T cells using TRIzol Reagent
according to the manufacturer’s directions (Invitrogen, Carslbad, CA). cDNA
was synthesized using M-MLV reverse transcription, random hexamer
primers, and 10 mM dNTP (Promega, Madison, WI). Real-time PCR was
performed in triplicates using SYBR Green PCR. The primer sequence genes
were as follows: FoxP3 forward primer: GTGGCATCATCCGACAAGG; Foxp3
reverse primer: TGTGGAGGAACTCTGGGAAT; RORgt forward primer
GCTGGTTAGGATGTGCCG; RORgt reverse primer: GGATGCTTTGGCGATGA;
IL-17a forward primer: CAATCCCACGAAAT CCAGGATG; IL-17a reverse
primer: GGTGGAGATTCCAAGGTGAGG; IL-1b forward primer:
CAGCTACGAATCTCCGACCAC; IL-1b reverse primer: GGCAGGGAACCAGCA
TCTTC; IL-21forward primer: ATGACTTGGTCCCTGAAT; IL-21 reverse primer:
ATTTGTGGAAGGTGGTTT; IL-22 forward primer: AGTGCTGTTCCCTCAATC; IL-
22 reverse primer: GCTTCCCATCTTCCTTTT; IL-23 forward primer: GGACAA
CAGTCAGTTCTGCTT; IL-23 reverse primer: CACAGGGCTATCAGGGAGC; IL-
23R forward primer: TCTTGTAGTCTGTAGGCTTGTGTTC; IL-23 R reverse
primer: TAATTCCAGTGAGCAGGTCCTATATG; GAPDH forward primer:
AAGAGCTACGAGCTGCCTGAC; GAPDH reverse primer: ATGGCCCAGCGG
ATGAG. The mRNA expressionwas determined by real-time PCR using SYBR
Green Master Mix (Applied Biosystems, Foster City, CA). Thermocycler
conditions comprised an initial holding at 50C for 2 minutes and a subse-
quent holding at 95C for 10 minutes, which was followed by a 2-step PCR
program at 95C for 15 seconds and 60C for 60 seconds for 40 cycles. Data
were collected and quantitatively analyzed on an ABI Prism 7500 HT
Sequence Detection System (ABI, Foster City, CA). Human GAPDH gene was
used as an endogenous control for sample normalization. Results were
presented as folds relative to the expression of GAPDH. Relative transcripts
were determined by the formula: 1/2(CTtarget-CTcontrol). Patient samples were
omitted if the target gene was below detection levels.
Measurement of Cytokines
Serum samples from consecutive patients were collected as soon as
aGVHD was diagnosed and before therapy was begun, and after aGVHD was
completely controlled. ELISAwas used tomeasure the serum concentrations
Figure 1. CD4þFoxP3þTreg cells decreased and Th17 cells increased in PBMCs of aGVHD patients. Peripheral blood of transplant patients was analyzed for
CD4þFoxP3þTreg and Th17 cell percentages. (A) Representative plot of ﬂow cytometric detection of CD4þFoxP3þTreg and Th17 cells. (B) (C) The percentages of Tregs
and Th17 cells were evaluated in patients without aGVHD (grade 0), mild aGVHD (grade 1 to 2), severe aGVHD (grade 3 to 4), and healthy donors (HD). *P < .05,
yP < .01, zP < .001.
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systems, Minneapolis, MN). All assays were performed in triplicates
according to the manufacturers’ instructions.
Statistical Analysis
Datawere analyzed by Pearson correlation andMann-Whitney test with
the use of Prism 5.00 forWindows software (Graph Pad Software, San Diego,
CA). P values <.05 were considered statistically signiﬁcant.
RESULTS
GVHD
All patients achieved a sustained and stable donor
engraftment. Among the 69 HSCT patients, 45 (65.2%)Figure 2. The expression of FoxP3 was down-regulated and RORgt expression was
patients without aGVHD (grade 0), patients with mild aGVHD (grade 1 to 2), patients
expression from PBMCs of patients without aGVHD (grade 0), patients with mild aGVH
(HD). (C) RORgt expression negatively correlated with FoxP3 expression (r2 ¼ .1237,patients developed aGVHD. Among the 45 patients who
developed aGVHD, 12 (26.7%) were grade 1, 16 (35.5%)
were grade 2, 5 (11.1%) were grade 3, and 12 (26.7%) were
grade 4. The median day of onset of aGVHD was 32
(range, 15 to 94). At 100 days after transplantation, the
cumulative incidence was 47.8% for grade 2 to 4 aGVHD,
and 24.6% for grade 3 to 4 aGVHD. Thirty-three episodes
of grade 2 to 4 aGVHD were treated with methylpred-
nisolone, and 21 (63.6%) episodes were treated success-
fully, whereas the 12 episodes that lacked adequate
response to the primary treatment were treated with
intravenous MTX at a dose of 10 mg once every 7 days,up-regulated in aGVHD patients. (A) Shows FoxP3 expression from PBMCs of
with severe aGVHD (grade 3 to 4), and healthy donors (HD). (B) Shows RORgt
D (grade 1 to 2), patients with severe aGVHD (grade 3 to 4), and healthy donors
P < .01). *P < .05, yP < .01, zP < .001.
Figure 3. Th17-associated cytokine expressions in GVHD patients. (A) IL-17, (B) IL-23, (C) IL-22, (D) TGF-b, (E) IL-6, (F) IL-21, (G) IL-1b, and (H) IL-23R expressions were
analyzed from PBMCs of patients without aGVHD (grade 0), patients with mild aGVHD (grade 1 to 2), patients with severe aGVHD (grade 3 to 4), and healthy donors
(HD). (A) IL-17 and (C) IL-22 expressions in CD4þ T cells were examined. (A) IL-17, (B) IL-23, and (C) IL-22 serum levels were also measured and compared among
aGVHD (grade 0), aGVHD (grade 1 to 2), and aGVHD (grade 3 to 4) patients. *P < .05, yP < .01, zP < .001.
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cell therapy. Patients were scheduled to receive at least 2
doses of MTX administrations for evaluation of the drug’s
efﬁcacy. Eight episodes showed improvement, but the
remaining 4 patients had exacerbated GVHD and subse-
quently died.
CD4þFoxP3þTreg Cells Decreased and Th17 Cells Increased
in PBMCs of aGVHD Patients
PBMCs from patients without aGVHD (grade 0), mild
aGVHD (grade 1 to 2), severe aGVHD (grade 3 to 4), and
healthy donors were collected and stained for CD4, IL-17, and
FoxP3. Representative ﬂow cytometry results are shown inFigure 1A. CD4þFoxP3þ T cells from patients with aGVHD
(grade 1 to 2 and grade 3 to 4) were signiﬁcantly decreased
compared with patients without aGVHD (grade 0) (P < .05,
P < .001) and healthy donors (P < .05, P < .01) (Figure 1B).
Furthermore, the percent of CD4þFoxP3þ Tregs was even
lower in severe aGVHD (grade 3 to 4) patients comparedwith
that of patients with mild aGVHD (grade 1 to 2) (P < .05),
suggesting the percent of CD4þFoxP3þ Tregs could be
correlated with the severity of the aGVHD. Percent of Th17
cells in PBMCs from severe aGVHD patients (grade 3 to 4)
was signiﬁcantly increased compared with patients with
mild aGVHD (grade 1 to 2) (P< .01), patients without aGVHD
(grade 0) (P < .001), and healthy donors (P < .01) (Figure 1C).
Figure 4. Correlation between Th17-related cytokine and FoxP3 and IL-17 expressions. Correlations among TGF-b (A), IL-6 (B) expressions, and FoxP3 expressionwere
analyzed. Correlations among IL-17 expression and TGF-b (C), IL-6 (D), IL-1b (E), IL-21 (F), IL-22 (G), IL-23 (H), serum levels of IL-23 (I), and IL-23R (J) expressions are
shown.
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increases in the percent of Th17 cells compared with patients
without aGVHD and healthy donors, but did not reach
statistical signiﬁcance.
To conﬁrm the changes of Treg and Th17 subsets, PBMCs
from the patients were measured for FoxP3 and RORgt
transcript levels by real-time PCR. All transplantation
patients had lower levels of FoxP3 expression compared
with healthy donors (Figure 2A). FoxP3 expression in
PBMCs from patients at the onset of aGVHD (grade 1 to 2
and grade 3 to 4) (within 24 to 48 hours of onset and before
active treatment) were signiﬁcantly decreased compared
with patients without aGVHD (grade 0) (P < .01, P < .001)
and healthy donors (both P < .001). In addition, patients
with severe aGVHD (grade 3 to 4) showed signiﬁcant lower
FoxP3 expression than the patients with mild aGVHD(grade 1 to 2) (P < .05), correlating with the ﬂow cytometry
results.
On the contrary, patients with aGVHD (grade 1 to 2 and
grade 3 to 4) displayed signiﬁcantly higher expression of the
Th17 master gene regulator RORgt than patients without
aGVHD (grade 0) (P < .01, P < .001) and healthy donors
(P < .05, P < .01) (Figure 2B). Similar to the ﬂow cytometry
results, the RORgt expression was also higher in severe
aGVHD patients (grade 3 to 4) than that in mild aGVHD
patients (grade 1 to 2) (P < .001). Moreover, the RORgt
expression was negatively correlated with the expression of
FoxP3 in all transplantation patients (r2 ¼ .1237, P < .01)
(Figure 2C). These data demonstrated the decrease of Treg
and increase of Th17 cells in aGVHD patients, suggesting the
imbalance of the 2 CD4þ T cell subsets may play important
role during the onset of aGVHD.
Figure 5. Dynamic changes of Th1, Th17, and FoxP3þ Treg Cells and IL-17, IL-23, and IL-22 expression during the onset and resolution of aGVHD (A) UPN 3, (B) UPN 5,
(C) UPN 13, and (D) UPN 16 were measured for their Treg, Th1, and Th17 cell percentages before, during, or after the onset of aGVHD. Serum levels of IL-17, IL-23, and
IL-22, as well as the transcripts of IL-17 and IL-22 RORgt in CD4þ T cells, were also examined. (E) Serum levels of IL-17, IL-23, and IL-22 in aGVHD patients were
measured before, during, and after the onset of GVHD. Each line represents an individual patient.
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Patients
The expressions of the Th-17-associated cytokines TGF-b,
IL-6, IL-1b, IL-21, IL-22, IL-23, and IL-23R in the PBMCs of
patients who underwent allo-HSCT were investigated. Both
IL-17 and IL-23 mRNA levels in PBMCs from patients at the
onset of severe aGVHD (grade 3 to 4) were signiﬁcantly
increased compared with patients of mild aGVHD (grade 1 to
2) (P< .001, P< .05), patients without aGVHD (grade 0) (both
P< .001), and healthy donors (P< .001, P< .01) (Figure 3A,B).
The IL-17 expressions in CD4þ T cells showed similar differ-
ences, except that the increase of expressions in mild aGVHD
reached statistical signiﬁcance (P < .05). Furthermore, theserum levels of IL-17 and IL-23 were signiﬁcantly higher in
patients with severe aGVHD (grade 3 to 4) than those in
patients with mild aGVHD (grade 1 to 2) (P < .001, P < .05)
and patients without aGVHD (both P < .001). Patients with
mild aGVHD (grade 1 to 2) also showed higher IL-17 serum
levels than the patients without aGVHD (P < .01). Interest-
ingly, IL-23R expression was also higher in aGVHD patients
(grade 1 to 2 and grade 3 to 4) than in patients without
aGVHD (grade 0) (P < .01, P < .001) and healthy donors
(P < .05, P < .01) (Figure 3H). IL-6 and IL-21 were up-
regulated in aGVHD (grade1 to 2 and grade 3 to 4) patients
compared with patients without aGVHD (grade 0) (P < .01,
P < .05) (Figure 3E,F). All transplantation patients had
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(Figure 3G). It was even higher in aGVHD (grade 1 to 2 and
grade 3 to 4) patients than in patients without aGVHD (grade
0) (both P < .001). Severe aGVHD patients (grade 3 to 4) also
showed higher IL-1b expression than mild aGVHD patients
(grade 1 to 2) (P < .001). Unlike the above cytokines, IL-22
expression in PBMCs signiﬁcantly decreased in severe
aGVHD (grade 3 to 4) patients compared with patients
without aGVHD and healthy donors (both P < .05). IL-22
expression in CD4þ T cells showed the same results. More-
over, it also signiﬁcantly decreased in mild aGVHD patients
(grade 1 to 2) compared with that in the patients without
aGVHD (P< .05). Furthermore, the serum levels of IL-22 were
signiﬁcantly reduced in patients with aGVHD and correlated
with the severity of aGVHD. TGF-b expression was not
signiﬁcantly changed among all patients and healthy donors,
except the expression in severe aGVHD patients (grade 3 to
4) was signiﬁcantly reduced compared with the patients
without aGVHD (P < .05).
We then explored the correlations between the examined
cytokines and FoxP3, as well as IL-17 expressions, in aGVHD
(grade 1 to 4) patients (Figure 4). TGF-b, but not IL-6, was
positively associated with FoxP3 expression (Figure 4A B). IL-
1b, IL-21, IL-23, and IL-23R expression were positively asso-
ciated with IL-17 expression (Figure 4E-H). The serum levels
of IL-23 were also positively correlated with IL-17 serum
levels (Figure 4I). It seemed that IL-6 was positively associ-
ated with IL-17 expression and IL-22 was negatively associ-
ated with IL-17 expression, but the correlation did not reach
the statistical signiﬁcance (Figure 4D,G). TGF-b showed no
correlation with IL-17 expression (Figure 4C). The results
demonstrated that the expression of most Th-17-associated
cytokines increased in aGVHD patients and their expressions
were signiﬁcantly associated with IL-17.
Dynamic Changes of Th1, Th17, and FoxP3þ Treg Cells and
IL-17, IL-22, IL-23 Expression during the Onset and
Resolution of aGVHD
To investigate the dynamic changes of Th1, Th17, and
FoxP3 Treg cells during the onset of aGVHD, 4 patients were
followed for their Th1, Th17, and FoxP3 Treg cell percentages
in PBMCs during the occurrence and resolution of aGVHD
(Figure 5A-D). In the patient with unique patient number
(UPN) 3, gut aGVHD (grade 3) occurred at days þ84 and
resolved after application of methylprednisolone (2 mg/kg)
in the next few days. Accordingly, we demonstrated rela-
tively higher levels of Th1 and Th17 and a lower level of
FoxP3þ Treg cell proportion in the PBMCs on day þ84
(Figure 5A). During the progressive resolution of aGVHD, Th1
and Th17 cells decreased to almost undetectable levels, with
an increase of Treg cells on day þ98. In line with clinical
manifestation and Th17 percentages, serum levels of IL-17
and IL-23, as well as IL-17 and RORgt transcript levels in
CD4þ T cells, dropped, but IL-22 serum levels and mRNA
expression in CD4þ T cells were lightly increased. In UPN 5,
we detected a very low level of Th1 and Th17 cells on
day þ59 after HSCT, corresponding to stable donor engraft-
ment and no aGVHD (Figure 5B). On day þ74, patients with
large area skin rashes (>75%) received methylprednisolone
(2 mg/kg). Subsequently, abdominal pain and diarrhea
occurred; FK506 and MTX 10 mg were given weekly. Corre-
sponding to aGVHD activation, we observed an increase of
Th1 and Th17 levels with a decrease of Treg cells. Serum
levels of IL-17 and IL-23, as well as IL-17 and RORgt transcript
levels in CD4þ T cells, increased with a slight decrease ofIL-22. In UPN 13, active GVHD (skin and liver involvement)
occurred at day þ36, which resolved after application of
methylprednisolone and MTX in the next few days. Accord-
ingly, we detected relatively higher levels of Th1 and Th17
cells and lower levels of Treg cells in PBMCs on day þ36,
which reversed when aGVHD was resolved on day þ75
(Figure 5C). Serum levels of IL-17 and IL-23, as well as IL-17
and RORgt transcript levels in CD4þ T cells, dropped after
GVHD improvement with a slight increase of IL-22 serum
levels. In UPN 16, who presented with a stable disease, we
detected relatively lower Th1 and Th17 levels and progres-
sively increased Treg levels from dayþ48 toþ83 (Figure 5D).
This trend was inverted after a severe aGVHD ﬂare occurring
on day þ94. This patient suffered from multiple organ
involvement (skin, liver, and gut) and was treated with
FK506, MTX, and CD25 monoclonal antibody. At this time
point, we detected an increase of Th1 and Th17 cells and
a signiﬁcant drop of Treg cells. Serum levels of IL-17 and IL-
23, as well as IL-17 and RORgt transcript levels in CD4þ T
cells, increased simultaneously. Moreover, when aGVHD
resolved to a stable disease on day þ108, Th1 and Th17 cells
decreasedwith an increase of Treg cells. Serum levels of IL-17
and IL-23, as well as IL-17 and RORgt transcript levels in
CD4þ T cells, also dropped. Both serum and transcription
levels of IL-22 were very low in this patient. However, the
serum level of IL-22 did slightly decrease when aGVHD
occurred.
To study the dynamic changes of Th17-associated cyto-
kine levels in the serum during the onset and resolution of
aGVHD, 9 patients were measured for their serum IL-17, IL-
23, and IL-22 levels before, during, and after aGVHD episodes
(Figure 5E). All patients showed increased IL-17 and IL-23
serum levels during the onset of aGVHD and the cytokine
levels dropped during the remission. On the contrary,
patients showed decreased IL-22 serum levels during the
onset of aGVHD and the cytokine levels increased during the
remission.
Collectively, the results demonstrated a reciprocal rela-
tionship between Treg and Th17 cells. Th17-associated
cytokine expression, especially IL-17 and IL-23, were
closely related to the occurrence and resolution of aGVHD.
The dynamic balance between the Th17 and FoxP3þ Treg
cells and changes of Th17-associated cytokines could be the
indicators of the disease progression.
DISCUSSION
In a total of 69 allo-HSCT patients, we ﬁrst extensively
studied the expression of Th17-associated cytokines, as well
as Th17 and Treg percentages, and compared them among
aGVHD patients, patients without aGVHD, and healthy
donors. Th17 and most Th17-associated cytokines were up-
regulated in aGVHD patients. The dynamic changes of Th17
and Treg cells, as well as Th17-associated cytokine levels,
during the onset and resolution of aGVHD suggested they
could be the indicators or therapeutic targets of aGVHD.
Many reports have already conﬁrmed the correlation
between the frequency of Tregs and the severity of aGVHD.
Miura et al. [32] reported that FoxP3 mRNA expression was
signiﬁcantly decreased in PBMCs from patients with GVHD
compared with patients without GVHD. Expression of FoxP3
was negatively correlated with the severity of GVHD. Rezvani
et al. [25] found that patients who received HSCT with lower
absolute numbers of CD4þFoxP3þ T cells had a greater risk of
developing GVHD. Our study conﬁrmed the negative corre-
lation between the frequency of Tregs and the severity of
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signiﬁcantly decreased frequency of CD4þFoxP3þ Treg cells
as compared with patients with aGVHD (grade 1 to 2). The
expression of FoxP3 was also lower in aGVHD patients
(Figure 2A).
Controversy exists in both mice and humans regarding
the role of Th17 cells in the pathogenesis of aGVHD, although
most of the studies indicated that Th17 promoted aGVHD.
Carlson et al. [33] reported that a high dose of in vitroe
differentiated Th17 cells mediated GVHD-related severe
cutaneous and pulmonary lesions. IL-17 was also found to
contribute to the early development of CD4-mediated GVHD
[12]. On the contrary, Yi et al. showed that IL-17/ donor T
cells had elevated Th1 differentiation and induced severe
aGVHD damage [11]. Iclozan et al. reported Th17 cells were
sufﬁcient but not necessary to induce aGVHD [13]. It was also
suggested that Th17 might augment tissue-speciﬁc damage
in skin and lung [34]. In humans, Dander et al. showed Th17-
mediated aGVHD [14]. However, a study suggested that
a Th17 to Treg ratio <1 was correlated with severe clinical
and pathologic GVHD [16]. There was a recent human study
showing that aGVHD was not associated with signiﬁcant
changes in the absolute numbers of the Th1 or Th17 cell
subsets [35]. However, the proportions of the Th subsets
could be more relevant to the overall function of the CD4þ T
cells. Our results from aGVHD patients demonstrated that
higher levels of Th17 and most Th17-associated cytokines
were associated with clinical aGVHD, suggesting a possible
role of Th17 and related cytokines in aGVHD pathogenesis.
Moreover, we also demonstrated an inverse correlation
between the proportion of Th17 and Treg cells during the
onset and resolution of aGVHD. This result suggested a lower
ratio of Th17 to Treg could indicate the progression of aGVHD
remission compared with the ratio at the onset of the
disease. Despite the possible involvement of the Th17 cells in
aGVHD, Th1 cells may still play a dominant role in aGVHD,
suggested by the similar and bigger changes of the Th1 cells
in the representative patients (Figure 5).
Although antithymocyte globulin (ATG) is recommended
for GVHD prophylaxis after allo-HSCT, evidence of efﬁcacy of
ATG is conﬂicting [36]. It has been suggested that ATG could
induce the generation of Treg cells [37]. A recent study also
showed that ATG during conditioning could reduce the
frequencies of Th17 cells [35]. Therefore, ATG may inﬂuence
the distributions of Th17 and Treg cells and the incidence of
aGVHD. There were 30 patients who were treated with ATG
during conditioning, and the overall frequencies of Th17 and
Treg cells could be inﬂuenced by this treatment.
The progression of aGVHD depends heavily on the
balance of proinﬂammatory and anti-inﬂammatory cyto-
kines in the milieu, in which donor-directed T cell response
occurs. In addition, the inﬂammatory milieu may destabilize
the program of both natural and induced Tregs, converting
them into inﬂammatory, effector-like phenotypes. Therefore,
modulation of the Th17-Treg balance by cytokine blockade is
a realistic and attractive strategy to prevent aGVHD. A large
amount of data have shown that Th17 generation, expansion,
stabilization, and function could be inﬂuenced by a set of
cytokines, including (TGF)-b, IL-1b, IL-6, IL-21, IL-22, IL-17,
and IL-23. We examined the expressions of the complete
panel of the cytokines that may inﬂuence the frequencies of
the Th17 cells with samples of the single cohort of patients.
In addition, IL-17 and IL-22 expression were also examined
with the puriﬁed CD4þT cells to exclude the inﬂuence of
other IL-17- and IL-22-producing cells. Furthermore, theserum levels of IL-17, IL-22, and IL-23 were also measured
and tracked before, during, and at the remission stage of
aGVHD to give a more complete picture of the expressions of
Th17-associated cytokines. The results from the representa-
tive patients also supported a close correlation between Th17
cells and their associated cytokines, especially IL-17 and IL-
23, at both transcriptional and serum levels.
IL-23 is not involved in the initial Th17 differentiation, but
is necessary for the generation of a completely functional
Th17 response [38]. Expression of IL-23 and IL-23R genes was
up-regulated during GVHD in mouse colon [19]. Das et al.
demonstrated that the selective protection of the colon that
occurs as a consequence of inhibition of IL-23 signaling
reduced GVHD without loss of the graft-versus-leukemia
effect [21]. Another study indicated that deﬁciency of p19
in the allogeneic donor transplantation might reduce the
inﬂammation caused by aGVHD [20]. In our study, in accor-
dance with the already described IL-23/Th17 axis, IL-23
mRNA expressions in patients with aGVHD were signiﬁ-
cantly higher than those in healthy donors, and IL-23 and IL-
23R expression were positively correlated with IL-17
expression. IL-23 serum levels were also elevated during
the onset of aGVHD and decreased during disease remission.
Our results strongly suggested a close correlation between
IL-23 and aGVHD, as well as Th17 function. It could be
a promising candidate for therapeutic targeting in aGVHD
patients.
IL-6, IL-1b, and IL-21 were also elevated in severe aGVHD
patients. Blockade of IL-1b has been shown to reduce
aGVHD-related mortality [39]. However, the clinical trial
using the same reagent did not show effectiveness in pre-
venting aGVHD [40]. IL-6 is one of the central mediators of
inﬂammation, which has a pivotal function in dictating
whether T cells differentiate into Tregs or Th17 cells. Tawara
et al. reported that anti-IL-6R mAb-mediated attenuation of
GVHD was independent of the direct effects on effector T cell
expansion or donor Tregs [18]. However, it may not be a good
candidate for therapeutic blockade because of its regulatory
role on both Th17 and Treg cells. IL-21 is produced by Th17
cells, and inhibition of IL-21 signaling on donor T cells
attenuated GVHD, particularly in the intestine [22,23]. In
humans, skin and colon samples obtained from patients with
no GVHD or grade 2 to 4 GVHD were analyzed for IL-21
protein expression. IL-21 protein-producing cells were
present in all gastrointestinal tract samples and 54% of skin
samples obtained from GVHD patients, but not from GVHD-
free controls. In a human xenogeneic GVHD model, human
IL-21-secreting cells were present in the colon of GVHD
recipients and were associated with elevated serum IL-21
levels [41]. Our results showed elevated IL-21 expression in
PBMCs of patients with aGVHD (grade 1 to 2 and grade 3 to 4)
compared with patients without aGVHD (grade 0), suggest-
ing the increased IL-21-producing cells in the circulation of
aGVHD patients.
IL-22 is expressed predominantly in Th1 cells and Th17
cells. It was the only cytokine we examined that decreased
and showed a negative correlation with IL-17 in aGVHD
patients. A recent study showed that IL-22 could protect
intestinal stem cells from inﬂammation-mediated tissue
damage and reduce the sensitivity to aGVHD [24]. Our
human studies support the protective role of IL-22 in aGVHD.
The discrepancies between the increase of Th17 cells and the
reduction of IL-22 expression in CD4þ T cells and serum
levels suggest that Th17 may not be the main source of IL-22,
which plays a role in aGVHD.
Y. Liu et al. / Biol Blood Marrow Transplant 19 (2013) 1421e1429 1429In conclusion, Th17 cells and most Th17-associated cyto-
kines were up-regulated in aGVHD patients. The dynamic
changes of Th17 and Treg proportions in PBMCs, as well as IL-
17 and IL-23 serum levels, could be indicators of the onset
and resolution of aGVHD. The imbalance of Th17 to Treg cells
and their related cytokines could contribute to the immune
dysregulation associated with aGVHD, which could be tar-
geted for the development of therapeutic strategies.ACKNOWLEDGMENTS
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